HIV-Associated Tuberculosis Epidemiology and Management
Summary
HIV-associated tuberculosis remains a leading cause of morbidity and mortality where the two epidemics overlap. People living with HIV (PLHIV) have a 20–30 times higher risk of progressing from latent to active tuberculosis due to impaired cell-mediated immunity. The global burden is greatest in sub-Saharan Africa and parts of Asia, where co-infection fuels both transmission and poor clinical outcomes. Key drivers include low CD4 T-cell counts, late HIV diagnosis, under-nutrition and gaps in tuberculosis preventive therapy. Diagnosis is complicated by atypical presentations, smear-negative disease and extrapulmonary involvement, requiring integrated use of molecular assays, chest imaging and clinical algorithms. Management hinges on early antiretroviral therapy to restore immune function, isoniazid preventive therapy to reduce incident disease and standard four-drug tuberculosis regimens with careful monitoring for drug–drug interactions. Strengthening infection control, active case finding and adherence support are critical to interrupt transmission and improve survival among PLHIV.
Research from Nature Portfolio
Recent analyses of national laboratory data have revealed inequities in tuberculosis testing across HIV and viral suppression strata. In a large South African cohort, per-capita testing was lowest among people without HIV and among those with suppressed viral load, yet test positivity peaked in unsuppressed PLHIV and in young adult males. Logistic modelling identified viral suppression as a key modifier of testing yield, underscoring the need for targeted screening policies that bridge gaps in both HIV care and tuberculosis case detection.
HIV-Associated Tuberculosis Epidemiology and Management publication trend
The graph below shows the total number of articles in hiv-associated tuberculosis epidemiology and management across all publications each year (not limited to Nature Index journals).
Technical terms
CD4 T-cell count: A laboratory measure of immune competence, with lower counts indicating greater vulnerability to opportunistic infections, including tuberculosis.
Incidence density rate (IDR): The number of new cases of disease per unit of person-time observed, often expressed per 100 person-years.
Isoniazid preventive therapy (IPT): Administration of isoniazid to PLHIV without active tuberculosis to reduce the risk of progression to disease.
Extrapulmonary tuberculosis (EPTB): Tuberculosis manifestations outside the lungs, including lymphatic, pleural, bone or central nervous system involvement, which may present atypically in PLHIV.
References
- Tuberculosis testing patterns in South Africa to identify groups that would benefit from increased investigation. Scientific Reports (2023).
- Tuberculosis and its associated risk factors among HIV-positive pregnant women in northwest Ethiopia: A retrospective follow-up study. Heliyon (2023).
- Incidence and risk factors for HIV-tuberculosis coinfection in the Cologne–Bonn region: a retrospective cohort study. Infection (2024).
- Dynamics of Matricellular Protein Levels in Blood Predict Recovery in Patients with Human Immunodeficiency Virus-Tuberculosis Coinfection. Viruses (2024).
- TUBERCULOSIS: EPIDEMIOLOGY AND CONTROL. Mediterranean Journal of Hematology and Infectious Diseases (2014).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Nature Index 2026 Regenerative medicine
Regenerative medicine has the potential to transform the treatment of chronic and life-threatening diseases. But major challenges remain, such as overcoming immune rejection and ensuring that new therapies are developed using more inclusive data sets. In this supplement, we explore the discoveries that are driving the field, the barriers that could limit its progress, and the teams and institutions that are making their mark.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.